RecruitingPhase 2NCT02991469
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Studying Juvenile idiopathic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- Sarilumab SAR153191 (REGN88)(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2018 – 2029
Study locations (29)
- Investigational Site Number : 0320004, San Miguel de Tucumán, Tucumán Province, Argentina
- Investigational Site Number : 1240110, Calgary, Alberta, Canada
- Investigational Site Number : 2460040, Helsinki, Finland
- Investigational Site Number : 2500041, Bron, France
- Investigational Site Number : 2500042, Montpellier, France
- Investigational Site Number : 2500040, Paris, France
- Investigational Site Number : 2760064, Berlin, Germany
- Investigational Site Number : 2760065, Berlin, Germany
- Investigational Site Number : 2760062, Hamburg, Germany
- Investigational Site Number : 2760060, Sankt Augustin, Germany
- Investigational Site Number : 2760063, Sendenhorst, Germany
- Investigational Site Number : 3000002, Thessaloniki, Greece
- Investigational Site Number : 3720001, Crumlin, Dublin, Ireland
- Investigational Site Number : 3800051, Genoa, Genova, Italy
- Investigational Site Number : 3800054, Milan, Milano, Italy
- +14 more locations on ClinicalTrials.gov
Collaborators
Regeneron Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02991469 on ClinicalTrials.govOther trials for Juvenile idiopathic arthritis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE3NCT07386587Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic ArthritisUniversity of Child Health Sciences and Children's Hospital, Lahore
- RECRUITINGPHASE3NCT06654882Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisDuke University
- RECRUITINGNCT07243782Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in KoreaNovartis Pharmaceuticals
- RECRUITINGNANCT07217782Pain in Juvenile ArthritisWashington University School of Medicine
- RECRUITINGNCT07185750Investigation of Catastrophizing of Pain Reported by Parents in JIA PatientsHacettepe University
- RECRUITINGNCT06806774Reliability and Validity of the Glittre Activities of Daily Living Test in Children and Adolescents With Juvenile Idiopathic ArthritisHacettepe University
- RECRUITINGNANCT07234747Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic ArthritisIstanbul University - Cerrahpasa
- RECRUITINGNANCT06474546Feasibility of a Diet Intervention for Juvenile ArthritisThe Hospital for Sick Children